Multiple myeloma breakthrough 2018

Size: px
Start display at page:

Download "Multiple myeloma breakthrough 2018"

Transcription

1 Multiple myeloma breakthrough 2018 Carfilzomib Can Lead to Cardiovascular Toxicity in Multiple Myeloma Patients. Get the latest science news with ScienceDaily's free newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader: Oct. 5, 2016 Findings by cancer researchers shed light on why treated cancers recur. The discovery could provide the key for reducing recurrence, and allow anti-cancer drugs to do their intended. Covering Every Angle of Oncology Practice. Click a cover below, to view more. Test results after stem cell transplant for multiple myeloma can confuse patients and doctors about cancer's status. bb2121 Continues to Show Potential in Multiple Myeloma. Then Wright enrolled in a clinical trial of a "living drug" that was made by extracting some of his own immune cells, adding genetic code so they would recognize his myeloma and reintroducing these weaponized cells into his body to attack his cancer, a type generally thought to be incurable. For now, this groundbreaking treatment is offered only in clinical trials and primarily to patients whose disease has relapsed after many therapies. Wright, for example, tried 11 regimens, or lines, of treatment before enrolling in the CAR-T cell trial. There is a robust discussion about whether this treatment could be used in patients with earlier stages of disease, though most experts say that is at least several years away. statement. "It appears that with this novel immunotherapy there may be a chance for cure in multiple myeloma, but we will need to follow patients much longer to confirm that.". Preliminary study: Antibody therapy reduces cancer stem cells in multiple myeloma. Personalized drug screening on horizon for multiple myeloma patients. Provider and Caregiver Connection: Addressing Patient Concerns While Managing Chemotherapy Induced Nausea and Vomiting. Precision medicine What does this term really mean and how do different researchers feel about it as we move into 2018? The defining feature of "precision medicine" is DNA sequencing of both people and diseased tissue (such as a tumor or a myeloma bone marrow sample) carried out on a huge scale to gather what is called "big data." Such a

2 project is being conducted by the Mayo Clinic and myeloma expert Dr. Keith Stewart, who directs Mayo's Center for Individualized Medicine. TJP1 protein may identify multiple myeloma patients most likely to benefit from proteasome inhibitors. Content on this website is for information only. It is not intended to provide medical or other professional advice. Minimal Residual Disease Status, Outcomes in Patients With Multiple Myeloma. Who Believes in Conspiracies? New Research Offers a Theory. CURE does not provide medical, diagnostic, or treatment advice. We're Closer Than Ever To Finding Cause Of Autism. segment aired on NPR about the project, Dr. Stewart call it "a very worthwhile investment," even though the specific value is yet unclear. But a skeptical Mayo Clinic colleague, scientist Dr. Michael Joyner, says he believes that directly studying each disease can be more fruitful than "collecting vast piles of information, hoping to make sense of it later.". Early CAR T data on P-BCMA-101 in refractory myeloma. The Good, The Bad, & The Semantically Imprecise - 10/5. A new Compendium providing updated clinical information to "Ask the Hematologist" articles published in The Hematologist from 2010 to 2015 is now available. Learn more. Harvard Medical School; Dana Farber Cancer Institute, Boston, MA. These example sentences are selected automatically from various online news sources to reflect current usage of the word 'myeloma.' Views expressed in the examples do not represent the opinion of Merriam-Webster or its editors. Send us feedback. J&J's Darzalex improves outcomes in multiple myeloma trial. More specifically, the FDA approval of Darzalex is for myeloma patients who have received at least three prior lines of therapy, including both an immunomodulatory agent and a proteasome inhibitor, and for patients who are "double refractory", meaning their disease no longer responds to treatment with at least one immunomodulatory agent and at least one proteasome inhibitor. Baylor had been diagnosed with multiple myeloma, a cancer that attacks bone marrow. Liz Szabo, Kaiser Health News, "'Breakthrough' Leukemia Drug Also Portends 'Quantum Leap' In Cost," 23 Aug Darzalex is an infused therapy, and it will be available in vials that come in two sizes: A smaller vial that contains 100 mg of the drug, and a larger vial that contains 400 mg. Combined infusion of CD19 and Bcma-specific chimeric antigen receptor T cells for RRMM: initial

3 safety and efficacy report from a clinical pilot study. Blood. 2017;130:506. The Good, The Bad, & The Semantically Imprecise - 10/5. Keep those drugs coming, thank you very much!. session ID when you navigate from page to page. This cookie stores just a. Darzalex is the second new myeloma therapy the FDA has approved this year, and additional approvals may be on the way. The agency gave the okay to Farydak (panobinostat) in February (see related Beacon news), and it is reviewing approval applications for two other potential myeloma therapies ixazomib and elotuzumab ( Empliciti ). Safety and efficacy of B-cell maturation antigen (BCMA)-specific chimeric antigen receptor T cells (CART-BCMA) with cyclophosphamide conditioning for refractory multiple myeloma (MM). Blood. 2017;130:505. The UK continues to lag behind in access and uptake of new cancer treatments and has some of the worst survival rates in Europe, the firm argued, noting: "Daratumumab monotherapy is currently reimbursed in 12 European countries. In contrast, since the launch of the 'new' Cancer Drugs Fund in July 2016, only one drug has been successfully added to the fund". Subscribe to America's largest dictionary and get thousands more definitions and advanced search ad free!. Scott - From what we've read, the initial work developing Darzalex was done in the Dutch laboratories of the Danish biotech company Genmab, which also organized the first clinical trial of the drug. Fan F, Zhao W, Liu J, et al. The warnings and precautions for Darzalex include infusion-related reactions and interference with certain blood tests including, in the case of some myeloma patients, the serum protein electrophoresis (SPEP) and serum immunofixation electrophoresis (IFE) tests that help measure a patient's response to treatment. And is one way more correct than the others?. Clinical responses with T lymphocytes targeting malignancy-associated κ light chains. J Clin Invest. 2016;126: The trial enrolled 559 patients who had relapsed after treatment with lenalidomide. Two hundred and eightyone patients were treated with pomalidomide (Pomalyst), bortezomib (Velcade), and low-dose dexamethasone; 278 were treated with only bortezomib and low-dose dexamethasone. All patients had prior lenalidomide (71% vs 69% lenalidomiderefractory); 72% vs 73% had prior bortezomib; and 70% vs 66% were refractory to their last treatment.

4 Median prior treatment lines was 2; 40% in the pomalidomide, bortezomib, and low-dose dexamethasone arm and 41% in the bortezomib and low-dose dexamethasone arm had 1 prior treatment line. Most notable perhaps, is the recent phase I clinical trial published by Dr. Jesus Berdeja and colleagues, which revealed that 15 (71%) of 21 MM patients who failed a median of seven lines of treatment experienced CRS following CAR T cell infusion. In this study, the authors used bb2121, a novel CAR that incorporates an anti-bcma singlechain variable fragment, a 4-1BB costimulatory motif, and a CD3-zeta T cell activation domain. Moreover, from 18 patients who received a high infusion dose, a good treatment response was observed in 17, with 10 achieving CR at a median follow-up of 40 weeks. This sparked the launch of the phase II KarMMa trial to investigate the difference in response to an infusion of 150 versus 300 million CAR T cells. From there, mechanisms of relapse and resistance to anti-bcma CAR T cell therapy, and the possibility of devising a potent combination of CAR T cells and a chemotherapeutic regimen require further study. Another study presented at the 2017 ASH Annual Meeting compared the response of highly refractory MM patients with high-risk cytogenetics to CAR T cells at different infusion dosages with and without lymphodepletion with cyclophosphamide. 11 Indeed, they found that a lower infusion dose led to lower response rates and efficacy, while the addition of cyclophosphamide to the regimen led to a higher median peak expansion of CAR T BCMA cells, which is associated with achieving a partial response or better. Furthermore, another pilot trial of eight patients simultaneously used both anti-cd19 and BCMA CAR T cells in addition to cyclophosphamide. 12 While this study demonstrated clinical benefit and collateral toxicities (CRS and prolonged cytopenias) similar to other trials, the small patient number and short followup of four weeks prevents them from drawing concrete conclusions at this point. Yet, this study addresses a main concern, which is the possibility of CAR T BCMA induced immune editing whereby residual MM cells decrease their BCMA expression following CAR T cell infusion, enab. WCLC 2018: Outdoor Air Pollution Exposure and Lung Cancer in Female Never-Smokers. Management of Clostridium difficile Infection in TEENren and Adolescents With Cancer

5 and Pediatric HSCT Recipients. Janssen said it is extremely concerned that the National Institute for Health and Care Excellence (NICE) has not recommended Darzalex for treatment of relapsed and refractory multiple myeloma in adults in preliminary guidelines. Should the Institute's position become final, patients who have failed nearly all existing treatment options will remain unable to access an innovative and much needed treatment for this incurable form of blood cancer on the NHS - whilst it is already reimbursed in several European countries, the firm stressed. Darzalex (daratumumab) holds a conditional license in Europe to treat adults with relapsed and refractory multiple myeloma who have been treated before with proteasome inhibitor and an immunomodulatory agent and whose disease as progressed on their last therapy. However, the cost watchdog has turned down NHS funding for the drug in an appraisal consultation document. Whilst the committee recognised the need for effective, welltolerated treatment for people with the disease who have had previous therapies, the quality of evidence presented meant that it could not fully interpret how clinically effective the drug is, NICE said. This high degree of uncertainty for clinical effectiveness meant that Darzalex' cost effectiveness results were unreliable and a most plausible ICER (incremental cost effectiveness ratio) could not be identified. Janssen says findings from a combined efficacy analysis of two mid-stage trials showed that after a mean follow-up of 20.7 months, the estimated median overall survival (OS) for Darzalex in these heavily pretreated patients was 20.1 months, with 65 percent surviving up to 12 months whereas current treatment options have shown around an average survival of five to nine months. The overall response rate (ORR) for the combined analysis was 31 percent, and 83 percent of patients achieved stable disease or better. "This decision is extremely disappointing and highlights that little has changed in the way that medicines are assessed in the UK," said Jenni. J&J's Darzalex improves outcomes in multiple myeloma trial. Durable remissions with BCMA-specific chimeric antigen receptor (CAR)-modified T cells in patients with refractory/relapsed multiple myeloma. J Clin Oncol. 2018; doi: /JCO _suppl.LBA3001. [Epub ahead of print]. Long-Term Outcomes With Anti PD-L1 Treatment in Metastatic Triple-Negative Breast

6 Cancer. After a median of 16 months, those who received pomalidome, bortezomib, and low-dose dexamethasone had a 39% lower risk of disease progression or death than those who received bortezomib and low-dose dexamethasone. The most common side effects of the drug combinations were neutropenia, infections, and thrombocytopenia, which were largely manageable. Harvard Medical School; Dana Farber Cancer Institute, Boston, MA. Ali SA, Shi V, Maric I, et al. T cells expressing an anti-b-cell maturation antigen chimeric antigen receptor cause remissions of multiple myeloma. Blood. 2016;128: Janssen seeks to expand use of multiple myeloma drug. Guo B, Chen M, Han Q, et al. Current treatment landscape for relapsed and/or refractory multiple myeloma. Nat Rev Clin Oncol. 2015;12: Acquired Clinical Resistance to IDH2 Inhibitors: Leukemia Finds Multiple Avenues for Escape. Cohen AD, Garfall AL, Stadtmauer EA, et al. WCLC 2018: Poziotinib in Stage IV NSCLC With Genetic Mutations. Combined infusion of CD19 and Bcma-specific chimeric antigen receptor T cells for RRMM: initial safety and efficacy report from a clinical pilot study. Blood. 2017;130:506. Dr. Roberts looks at two studies that help us better understand why patients with IDH2-mutant acute myeloid leukemia may not maintain double remissions. Go to the App Store or Google Play and search for 'PharmaTimes' to download our free app.